New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
pharmaphorum4d
Merck's oral MS drug finally gets FDA okay
Merck KGaA fought for years to get the drug approved after rejection by ... which is associated with unpleasant gastrointestinal side effects. Moreover, it could also help defend Biogen’s ...
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Yahoo Finance24d
Europe Approves Merck's Cancer Drug For Two Indications
Europe Approves Merck's Cancer Drug For Two Indications On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral hypoxia ...
The Hindu8d
New version of Merck's cancer drug faces possible patent battle: reports
Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...
Seeking Alpha23d
Merck wins EU nod for Welireg against two kidney cancer indications
The approvals are backed by Merck’s (NYSE:MRK) LITESPARK-004 and LITESPARK-005 trials, respectively. An expert panel of the EU drug regulator, the European Medicines Agency, endorsed the ...
Business Insider9d
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of its crucial cancer drug Keytruda. Enzyme Dispute ...